NCT07919678ClinicalTrials.gov
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)
En bref
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…
Phase 3656 participants recherchés40 sites2 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT07919678Ouvrir cette fiche sur ClinicalTrials.govSynchronisé il y a 2 semaines
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 3 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 40 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.
How this score is built
- Enrolment28/40
656 participants (target)
- Site count19/25
40 sites
- Country count7/15
2 countries
- Planned duration7/10
Planned over about 24 months
- Sponsor scale10/10
Pfizer has led 630 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
Affections
- Obesity
- Overweight
- Osteoarthritis of the Knee
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 18 Years – Aucun maximum |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 3 |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | QUADRUPLE (4) |
| Recrutement | 656 participants recherchés |
Promoteur et collaborateurs
- Pfizer Promoteur
Groupes et interventions
- PlaceboPLACEBO_COMPARATOR
Participants will receive placebo as subcutaneous injection
- Arm 1: Berobenatide Once MonthlyEXPERIMENTAL
Participants will receive berobenatide by subcutaneous injection.
- Arm 2: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
- Arm 3: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
Interventions
- Médicament Berobenatide
Subcutaneous Injection
- Autre Placebo
Subcutaneous Injection
Critères de jugement
Critère de jugement principal
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score
Délai Baseline and Week 52
Critère de jugement secondaire
Percent change from baseline in Body Weight
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in High-Sensitivity C-Reactive Protein
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in WOMAC Physical Function Subscale score
Délai Baseline and Week 52
Critère de jugement secondaire
Percentage of participants with ≥50% reduction in the WOMAC pain subscale score
Délai Baseline and Week 52
Critère de jugement secondaire
Percentage of participants with ≥30% reduction in the WOMAC pain subscale score
Délai Baseline and Week 52
Critère de jugement secondaire
Proportion of participants with utilization of protocol specified pain medication during the washout period
Délai Baseline and Week 52
Critère de jugement secondaire
Amount of protocol specified pain medication during the washout period
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in WOMAC stiffness score
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in WOMAC total score
Délai Baseline and Week 52
Critère de jugement secondaire
Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score
Délai Baseline and Week 52
Critère de jugement secondaire
Proportion of participants meeting OMERACT-OARSI
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in Average Pain Intensity-Numerical Rating Score
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in Worst Pain Intensity -Numerical Rating Score
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in SF-36 domain scales and component summary scales
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in Body Weight
Délai Baseline and Week 52
Critère de jugement secondaire
Change from Baseline in Body Mass Index
Délai Baseline and Week 52
Critère de jugement secondaire
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Délai Baseline and Week 52
Critère de jugement secondaire
Number of Participants with Serious Adverse Events (SAE)
Délai Baseline and Week 52
Critère de jugement secondaire
Number of Participants with AE leading to permanent discontinuation from study intervention or study
Délai Baseline and Week 52
Critère de jugement secondaire
Number of Participants with Adverse Events of Special Interest (AESI)
Délai Baseline and Week 52
Critère de jugement secondaire
Number of Participants with Clinical laboratory abnormalities
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in timed walking distance at Week 52
Délai Baseline and Week 52
Critère de jugement secondaire
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function
Délai Baseline and Week 52
Critère de jugement secondaire
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain
Délai Baseline and Week 52
Critère de jugement secondaire
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function
Délai Baseline and Week 52
Critère de jugement secondaire
Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in WPAI:GH Work productivity loss score
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in WPAI:GH Activity impairment score
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in Systolic Blood Pressure (SBP)
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in Diastolic Blood Pressure (DBP)
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in Total Cholesterol
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in High-density lipoprotein cholesterol (HDL-C)
Délai Baseline and Week 52
Critère de jugement secondaire
Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in Non-HDL Cholesterol
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol
Délai Baseline and Week 52
Critère de jugement secondaire
Change from baseline in Triglycerides
Délai Baseline and Week 52
Dates
| Date de début | 26 octobre 2026 (réelle) |
|---|---|
| Achèvement principal | 22 août 2028 (estimée) |
| Achèvement | 10 octobre 2028 (estimée) |
| Première publication | 5 novembre 2026 (réelle) |
| Dernière mise à jour | 5 novembre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | octobre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
7 sites sont en recrutement
Canada
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Bluewater Clinical Research Group Inc. | Sarnia | Ontario | Pas encore en recrutement |
United States
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Albuquerque Clinical Trials, Inc. | Albuquerque | New Mexico | Pas encore en recrutement |
| Charlottesville Medical Research Center, LLC | Charlottesville | Virginia | Pas encore en recrutement |
| Northwestern University Feinberg School Of Medicine | Chicago | Illinois | Pas encore en recrutement |
| Great Lakes Clinical Trials, LLC dba Flourish Research | Chicago | Illinois | Pas encore en recrutement |
| Northwestern Medicine | Chicago | Illinois | Pas encore en recrutement |
| Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG) | Chicago | Illinois | Pas encore en recrutement |
| Northwestern Memorial Hospital, Investigational Drug Service | Chicago | Illinois | Pas encore en recrutement |
| Clinical Research of West Florida, Inc. | Clearwater | Florida | Pas encore en recrutement |
| Skylight Health Research | Colorado Springs | Colorado | Pas encore en recrutement |
| Mercy Family Clinic | Dallas | Texas | Pas encore en recrutement |
| Universal Axon Clinical Research LLC | Doral | Florida | En recrutement |
| Altoona Center For Clinical Research | Duncansville | Pennsylvania | En recrutement |
| Headlands Research California, LLC | Escondido | California | Pas encore en recrutement |
| Profound Research LLC | Farmington Hills | Michigan | En recrutement |
| Cedar Health Research | Fort Worth | Texas | Pas encore en recrutement |
| Novant Health Granite Quarry Internal Medicine (knee x-ray) | Granite Quarry | North Carolina | Pas encore en recrutement |
| BRCR Global Louisiana | Gretna | Louisiana | Pas encore en recrutement |
| JCCT-JUNO NW Houston | Houston | Texas | Pas encore en recrutement |
| Westside Center for Clinical Research | Jacksonville | Florida | Pas encore en recrutement |
| Activian Clinical Research | Kingwood | Texas | Pas encore en recrutement |
| Renstar Medical Research | Lady Lake | Florida | Pas encore en recrutement |
| Monroe Biomedical Research | Monroe | North Carolina | En recrutement |
| AMR Clinical | Norman | Oklahoma | Pas encore en recrutement |
| Renstar Medical Research | Ocala | Florida | Pas encore en recrutement |
| Prospective Research Innovations Inc. | Rancho Cucamonga | California | Pas encore en recrutement |
| Accellacare - Salisbury | Salisbury | North Carolina | Pas encore en recrutement |
| Consano Clinical Research, LLC | Shavano Park | Texas | Pas encore en recrutement |
| Revive Research Institute, Inc. | Sterling Heights | Michigan | En recrutement |
| Clinical Research Atlanta | Stockbridge | Georgia | Pas encore en recrutement |
| Clinical Research of West Florida, Inc. | Tampa | Florida | Pas encore en recrutement |
| AMR Clinical | Tempe | Arizona | Pas encore en recrutement |
| DM Clinical Research | Tomball | Texas | Pas encore en recrutement |
| Solace Clinical Research | Tustin | California | Pas encore en recrutement |
| Velocity Clinical Research, Waco | Waco | Texas | Pas encore en recrutement |
| Elevate Clinical Research | Wichita | Kansas | Pas encore en recrutement |
| Delaney Radiologist | Wilmington | North Carolina | En recrutement |
| Accellacare | Wilmington | North Carolina | En recrutement |
| North Georgia Internal Medicine | Woodstock | Georgia | Pas encore en recrutement |
| North Georgia Clinical Research, LLC | Woodstock | Georgia | Pas encore en recrutement |
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
Aucun changement n'a été enregistré depuis que nous avons intégré cette fiche pour la première fois.
Un changement est enregistré chaque fois que le promoteur met à jour la fiche du registre. Le statut, les dates, le recrutement et les sites apparaissent ici au fur et à mesure de leur évolution.